Breakdown | ||
Dec 2024 | Dec 2023 | Dec 2022 |
---|---|---|
Income Statement | Total Revenue | |
0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | 0.00 | 0.00 | EBIT |
0.00 | -4.68M | -3.86M | EBITDA |
0.00 | -4.64M | -3.80M | Net Income Common Stockholders |
16.51M | -4.94M | -3.21M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |
1.19M | 4.59M | 8.26M | Total Assets |
2.86M | 5.26M | 9.33M | Total Debt |
526.00K | 171.00K | 271.00K | Net Debt |
526.00K | -4.42M | -7.99M | Total Liabilities |
6.85M | 17.31M | 16.41M | Stockholders Equity |
-2.00K | -15.48M | -10.66M |
Cash Flow | Free Cash Flow | |
-8.42M | -4.54M | -3.38M | Operating Cash Flow |
-8.40M | -4.53M | -3.33M | Investing Cash Flow |
-22.00K | 573.00K | -524.00K | Financing Cash Flow |
5.10M | 522.00K | 2.75M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
63 Neutral | $12.46B | 9.56 | 8.14% | 17044.64% | 12.63% | -4.25% | |
40 Underperform | $6.14M | ― | 422.38% | ― | -95.07% | 40.41% | |
39 Underperform | $6.06M | ― | -248.97% | ― | ― | 57.83% | |
36 Underperform | $7.12M | ― | -233.67% | ― | ― | -1786.46% | |
34 Underperform | $8.56M | ― | ― | ― | -73095.97% | ||
27 Underperform | $9.49M | ― | -490.03% | ― | ― | 99.64% |
On April 23, 2025, Silexion Therapeutics announced a strategic collaboration with Catalent to develop advanced siRNA formulations and conduct clinical manufacturing activities for SIL204, their next-generation siRNA candidate. This partnership aims to optimize SIL204’s delivery formulations for targeting KRAS-driven cancers, building on promising preclinical results and supporting Silexion’s strategy to advance SIL204 toward clinical trials, with potential regulatory submissions planned for 2025 and 2026.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.
Silexion Therapeutics is currently facing significant financial challenges, with zero revenue and negative equity posing major risks. The technical analysis reflects bearish momentum, and the valuation metrics highlight the speculative nature of the stock. However, recent corporate events, particularly the progress in SIL204, provide some optimism. Overall, the stock’s score is low, reflecting the high risks and uncertain future prospects.
To see Spark’s full report on SLXN stock, click here.
On March 28, 2025, Silexion Therapeutics announced an expanded development plan for its siRNA candidate, SIL204, following promising preclinical data. The plan includes a dual-route administration strategy to treat KRAS-driven pancreatic cancer, integrating systemic and intratumoral delivery methods. This approach aims to address the aggressive nature of KRAS-driven cancers, characterized by high mortality and limited treatment options. Building on previous clinical results, Silexion plans further studies and regulatory submissions in 2025 and 2026, potentially advancing SIL204 into the next stage of clinical development.
On March 5, 2025, Silexion Therapeutics announced positive initial data from the systemic administration of SIL204 in orthotopic pancreatic cancer models. The data demonstrated SIL204’s efficacy in reducing both primary tumor growth and metastatic spread, marking a significant advancement in their development program. The findings validate SIL204’s effectiveness in a clinically relevant setting and suggest potential for treating both primary and metastatic pancreatic cancer with a minimally-invasive delivery method. Silexion is exploring an expanded development plan for SIL204 based on these results.